Xuanzhu Biopharmaceutical Co Ltd

02575

Company Profile

  • Business description

    Xuanzhu Biopharmaceutical Co Ltd is an innovation-driven biopharmaceutical company in China, leveraging its understanding of China's pharmaceutical industry and insights of its clinical needs to improve patient health and life. It has over ten drug assets under active development covering digestive diseases, oncology, and NASH. Its track record also includes the successful development of four drug candidates that were subsequently transferred and/or out-licensed to pharmaceutical companies. Its pipeline is staggered and complementary in structure, covering both validated targets with druggability as well as new mechanisms of action and drug modalities, established therapeutic areas such as oncology, and high-growth potential therapeutic areas such as NASH.

  • Contact

    Zhubang 2000 Business Center
    2107, Building 2
    Balizhuang Xili
    Chaoyang District
    Beijing
    CHN

    https://www.xzenithbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    342

Stocks News & Analysis

stocks

SpaceX’s IPO filing: Big spending, big losses

The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
stocks

ASX tech share tracking below guidance

Moat Rating downgraded for overvalued shares.
stocks

After plunge ASX blue chip undervalued

This company earns a moat from our analysts.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,862.5012.200.14%
CAC 408,117.42135.661.70%
DAX 4024,737.24336.591.38%
Dow JONES (US)50,009.35645.471.31%
FTSE 10010,432.34101.790.99%
HKSE25,764.99113.870.44%
NASDAQ26,270.36399.651.54%
Nikkei 22561,810.642,006.233.35%
NZX 50 Index12,833.1572.120.57%
S&P 5007,432.9779.361.08%
S&P/ASX 2008,641.2013.200.15%
SSE Composite Index4,186.0323.850.57%

Market Movers